Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells

Biochem Biophys Res Commun. 2008 Jun 20;371(1):110-3. doi: 10.1016/j.bbrc.2008.04.006. Epub 2008 Apr 10.

Abstract

The primary targets for SARS-CoV infection are the epithelial cells in the respiratory and intestinal tract. The angiotensin-converting enzyme 2 (ACE-2) has been identified as a functional receptor for SARS-CoV. ACE-2 has been shown to be expressed at the apical domain of polarized Calu-3 cells. In this report, interferon alfacon 1 was examined for inhibitory activities against SARS-CoV on human lung carcinoma epithelial Calu-3 cell line and the other three African green monkey kidney epithelial cell lines. Interferon alfacon 1 demonstrated significant antiviral activity in neutral red uptake assay and virus yield reduction assay. The data might provide an important insight into the mechanism of pathogenesis of SARS-CoV allowing further development of antiviral therapies for treating SARS infections.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use
  • Bronchi / virology*
  • Cell Line
  • Cell Line, Tumor
  • Humans
  • Interferon Type I / pharmacology*
  • Interferon Type I / therapeutic use
  • Interferon-alpha
  • Recombinant Proteins
  • Respiratory Mucosa / virology*
  • Severe Acute Respiratory Syndrome / drug therapy
  • Severe Acute Respiratory Syndrome / virology*
  • Severe acute respiratory syndrome-related coronavirus / drug effects*
  • Severe acute respiratory syndrome-related coronavirus / physiology
  • Virus Replication / drug effects*

Substances

  • Antiviral Agents
  • Interferon Type I
  • Interferon-alpha
  • Recombinant Proteins
  • interferon alfacon-1